Elgene Lim

Prof. Elgene Lim

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2021 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
SWSunny Z. Wu
Sunny Z. Wu
GAGhamdan Al-Eryani
Ghamdan Al-Eryani
DRDaniel Lee Roden
Daniel Lee Roden
SJSimon Junankar
Simon Junankar
KHKate Harvey
Kate Harvey
ASAlexander Swarbrick
Alexander Swarbrick

2 August 2009 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
KFk Con Fab
k Con Fab
ELElgene Lim
Elgene Lim
FVFrançois Vaillant
François Vaillant
DWDi Wu
Di Wu
NFNatasha C Forrest
Natasha C Forrest
GLGeoffrey J Lindeman
Geoffrey J Lindeman

23 March 2014 in Nature
Verified
Journal Article
Open access
PDF file
XCXi Chen
Xi Chen
DIDimitrios Iliopoulos
Dimitrios Iliopoulos
QZQING ZHANG
QING ZHANG
QTQianzi Tang
Qianzi Tang
MGMatthew B. Greenblatt
Matthew B. Greenblatt
LGLaurie H. Glimcher
Laurie H. Glimcher
This study finds that triple-negative breast cancers (TNBC) show an increased basal level of endoplasmic reticulum stress and activation of the XBP1 branch of the unfolded protein response; furthermore, XBP1 promotes tumour formation of TNBC cell lines by interacting with and regulating HIF1α. Laurie Glimcher and colleagues report that in triple-negative breast cancers (TNBCs), the tumour cells show an increased basal level of endoplasmic reticulum stress and activation of the XBP1 branch of the unfolded protein response, a major cellular stress response pathway in the tumour microenvironment. TNBC tumours lack receptors for oestrogen, progesterone and HER2, making them recalcitrant to many drugs through an absence of targets. The authors go on to show that XBP1 promotes tumour formation in TNBC cell lines by interacting with and regulating HIF1α in the absence of hypoxia. This study highlights an important link between two major stress pathways in TNBCs and suggests possible therapeutic interventions for this aggressive form of breast cancer. Cancer cells induce a set of adaptive response pathways to survive in the face of stressors due to inadequate vascularization1. One such adaptive pathway is the unfolded protein (UPR) or endoplasmic reticulum (ER) stress response mediated in part by the ER-localized transmembrane sensor IRE1 (ref. 2) and its substrate XBP1 (ref. 3). Previous studies report UPR activation in various human tumours4,5,6, but the role of XBP1 in cancer progression in mammary epithelial cells is largely unknown. Triple-negative breast cancer (TNBC)—a form of breast cancer in which tumour cells do not express the genes for oestrogen receptor, progesterone receptor and HER2 (also called ERBB2 or NEU)—is a highly aggressive malignancy with limited treatment options7,8. Here we report that XBP1 is activated in TNBC and has a pivotal role in the tumorigenicity and progression of this human breast cancer subtype. In breast cancer cell line models, depletion of XBP1 inhibited tumour growth and tumour relapse and reduced the CD44highCD24low population. Hypoxia-inducing factor 1α (HIF1α) is known to be hyperactivated in TNBCs9,10. Genome-wide mapping of the XBP1 transcriptional regulatory network revealed that XBP1 drives TNBC tumorigenicity by assembling a transcriptional complex with HIF1α that regulates the expression of HIF1α targets via the recruitment of RNA polymerase II. Analysis of independent cohorts of patients with TNBC revealed a specific XBP1 gene expression signature that was highly correlated with HIF1α and hypoxia-driven signatures and that strongly associated with poor prognosis. Our findings reveal a key function for the XBP1 branch of the UPR in TNBC and indicate that targeting this pathway may offer alternative treatment strategies for this aggressive subtype of breast cancer.

22 November 2016 in Cancer and Metastasis Reviews
Verified
Journal Article
Closed access
PDF file
CCChristine L. Chaffer
Christine L. Chaffer
BJBeatriz P. San Juan
Beatriz P. San Juan
ELElgene Lim
Elgene Lim
RWRobert A. Weinberg
Robert A. Weinberg

7 July 2010 in Bioinformatics
Verified
Journal Article
Open access
DWDi Wu
Di Wu
ELElgene Lim
Elgene Lim
FVFrançois Vaillant
François Vaillant
MAMarie-Liesse Asselin-Labat
Marie-Liesse Asselin-Labat
JVJane E. Visvader
Jane E. Visvader
GSGordon Smyth
Gordon Smyth
Motivation: A gene set test is a differential expression analysis in which a P-value is assigned to a set of genes as a unit. Gene set tests are valuable for increasing statistical power, organizing and interpreting results and for relating expression patterns across different experiments. Existing methods are based on permutation. Methods that rely on permutation of probes unrealistically assume independence of genes, while those that rely on permutation of sample are suitable only for two-group comparisons with a good number of replicates in each group. Results: We present ROAST, a statistically rigorous gene set test that allows for gene-wise correlation while being applicable to almost any experimental design. Instead of permutation, ROAST uses rotation, a Monte Carlo technology for multivariate regression. Since the number of rotations does not depend on sample size, ROAST gives useful results even for experiments with minimal replication. ROAST allows for any experimental design that can be expressed as a linear model, and can also incorporate array weights and correlated samples. ROAST can be tuned for situations in which only a subset of the genes in the set are actively involved in the molecular pathway. ROAST can test for uni- or bi-direction regulation. Probes can also be weighted to allow for prior importance. The power and size of the ROAST procedure is demonstrated in a simulation study, and compared to that of a representative permutation method. Finally, ROAST is used to test the degree of transcriptional conservation between human and mouse mammary stems. Availability: ROAST is implemented as a function in the Bioconductor package limma available from www.bioconductor.org Contact: smyth@wehi.edu.au Supplementary information: Supplementary data are available at Bioinformatics online.

1 October 2018 in The Lancet Oncology
Verified
Journal Article
Closed access
VGViviana Galimberti
Viviana Galimberti
BCBernard F Cole
Bernard F Cole
GVGiuseppe Viale
Giuseppe Viale
PVPAOLO VERONESI
PAOLO VERONESI
EVElisa Vicini
Elisa Vicini
MTM. Thorburn
M. Thorburn